<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109450">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149264</url>
  </required_header>
  <id_info>
    <org_study_id>000127</org_study_id>
    <nct_id>NCT02149264</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males</brief_title>
  <official_title>A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, open-label, non-randomized, clinical trial to evaluate the efficacy and
      safety of FE 999303 (Testosterone Gel) in adult hypogonadal males.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The percentage of subjects whose average concentration (Cave(0-24)) serum total testosterone levels are ≥300 and ≤1050 ng/dL</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects whose Cave(0-24) serum total testosterone levels are ≥300 and ≤1050 ng/dL</measure>
    <time_frame>Days 14, 35 and 56</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in International Index of Erectile Function (IIEF) score</measure>
    <time_frame>Days 35 and 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Multidimensional Assessment of Fatigue (MAF) score</measure>
    <time_frame>Days 35 and 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Short Form-12 Health Survey (SF-12) score</measure>
    <time_frame>Days 35 and 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration (Cave) for total testosterone and dihydrotestosterone</measure>
    <time_frame>Days 14, 35, 56 and 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUCτ) for total testosterone and dihydrotestosterone</measure>
    <time_frame>Days 14, 35, 56 and 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which the maximum concentration occurs (Tmax) for total testosterone and dihydrotestosterone</measure>
    <time_frame>Days 14, 35, 56 and 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration observed (Cmax) for total testosterone and dihydrotestosterone</measure>
    <time_frame>Days 14, 35, 56 and 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration observed (Cmin) for total testosterone and dihydrotestosterone</measure>
    <time_frame>Days 14, 35, 56 and 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Adult Male Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone Gel (FE 999303)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Gel (FE 999303)</intervention_name>
    <description>Testosterone Gel delivered using an applicator</description>
    <arm_group_label>Testosterone Gel (FE 999303)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18-75 years of age

          -  Two serum testosterone levels &lt;300 ng/dL

        Exclusion Criteria:

          -  Previous use of the study drug

          -  History of prostate or breast cancer

          -  Prostate-Specific Antigen (PSA) ≥3 ng/dL

          -  Subject is sexually active and not willing to use adequate contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Lawrence Township</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Purchase</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
